8-K current report · filed Oct 21, 2026

Abbott Laboratories (ABT) 8-K Current Report: October 21, 2026

Item 8.01Item EX-99.1ABT overview

Short answer

Abbott Laboratories (ABT) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Planned separation of global nutrition business into an independent, publicly traded company.

Abbott Laboratories 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Planned separation of global nutrition business into an independent, publicly traded company
  • Potential portfolio simplification, allowing Abbott to focus on remaining healthcare businesses
  • Exhibit 99.1 contains the announcement’s transaction details and expected timeline

Item EX-99.1 · Exhibit EX-99.1

  • Planned tax-free spin-off gives Abbott shareholders shares in both companies, subject to approvals and Form 10 effectiveness
  • Nutrition business targets independence by end-2027, with approximately $8.5B sales, 16,000 employees and 14 manufacturing sites
  • Post-separation Abbott expected to retain approximately $42B sales and focus on devices, diagnostics, biowearables and established medicines
  • Combined dividends expected to equal Abbott’s dividend at separation, while one-time transaction charges remain forthcoming
  • Daniel Salvadori designated CEO of the new Nutrition company, reducing leadership uncertainty ahead of separation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Abbott Laboratories 8-K filings

Get the next ABT 8-K as it lands

Follow ABT for push alerts, or ask the research agent what this filing means.